TABLE 1.
Demographics and prevalence of autoantibodies
| All patients (n = 47) | Moderate patients (n = 31) | Critical patients (n = 16) | |
|---|---|---|---|
| Age, years | 68 (25–90) | 61 (25–90) | 71 (26–85) |
| Female | 19 (40.4%) | 13 (41.9%) | 6 (37.5%) |
| Deceased | 4 (8.5%) | 0 (0.0%) | 4 (25.0%) |
| ANA (all patterns) | 10 (21.3%) | 8 (25.8%) | 2 (12.5%) |
| Nucleolar | 4 | 4 | |
| Nucleolar with dense fine speckled | 1 | 1 | |
| Speckled | 1 | 1 | |
| Speckled with cytoplasmic | 1 | 1 | |
| Proliferating cell nuclear antigen | 1 | 1 | |
| Nuclear dots | 1 | 1 | |
| Peripheral (rim) | 1 | 1 | |
| ANA titer | 1:40 (1:40–1:640) | 1:60 (1:40–1:640) | 1:40 (1:40–1:40) |
| Anti‐CCP antibody | 1 (2.1%) | 0 (0.0%) | 1 (6.3%) |
| ANA seroconversion/seroreversion | 2/16 (12.5%) | 2/11 (18.2%) | 0/5 (0.0%) |
| Anti‐CCP seroconversion/seroreversion | 1/16 (6.3%) | 0/11 (0.0%) | 1/5 (20.0%) |
Data are presented as medians (ranges) or numbers (percentages).
Abbreviations: ANA, antinuclear antibody; CCP, cyclic citrullinated peptide.